A 2007 double-blind, multicenter trial (n=102) showed ALC 1,500 mg/day significantly improved tender point count, total myalgic score, depression, and musculoskeletal pain compared to placebo.[9] A 2015 RCT found ALC 1,500 mg/day comparable to duloxetine 60 mg/day for pain and depression.[8] Most notably, a 2023 RCT demonstrated that adding PEA 1,200 mg/day + ALC 2,000 mg/day to ongoing duloxetine + pregabalin therapy produced significantly greater improvements in Widespread Pain Index, FIQR, and FASmod scores.[7] Role in Treatment: ALC can be used as monotherapy or adjunctive therapy in fibromyalgia
Anti-heartburn medicine reduces stomach acid production, providing relief from the burning that compounds the nausea
Fat oxidation rates, NAD+ levels, and insulin sensitivity improvements gained during the cycle will decline unless maintained through continued caloric deficit and training stimulus
Even during this titration period, injections remain on a once-weekly schedule unless otherwise directed
Boucher, H
